HIV and Hepatitis B CoInfection

Transcription

1 HIV and Hepatitis B CoInfection Douglas G. Fish, MD June 3, yo male with AIDS who had fallen out of care and returned in October 2013 Last seen in November 2012 CD4 at that time 340 cells/cmm HIV RNA 307 copies/ml HAART was tenofovir/emtricitabine (Truvada) and raltegravir (Isentress) HIV diagnosed in 1995 Only has K103N mutation from 5 prior resistance tests, dating to 2002 History 1

5 Current antiviral agents can control, but not eliminate, hepatitis B virus (HBV). HBV establishes a stable, nuclear covalently closed circular DNA (cccdna, or episomal DNA). A double-stranded DNA that originates in a linear form that gets ligated by means of DNA ligase to a covalently closed ring Transcription of viral DNA can occur from this cccdna form. cccdna Lucifora J et al. Science 14 March 2014: Vol. 343 no pp HBV persists in the liver even after serologic conversion to surface Ab positive. Can occur with severe immune suppression seen with HIV, including: Following immune reconstitution with antiretroviral therapy Discontinuation of antiretroviral drugs that have anti- HBV activity Drug-induced liver injury Superinfection with other hepatitis viruses. Rituximab, used to treat NHL, CLL, RA, and some forms of vasculitis, and Ofatumumab, used to treat CLL, also associated with reactivation of HBV Gupta S et al. J Clin Gastroenterol1990;12:562 Mitka M JAMA. 2013;310(16):1664. Reactivation Hepatitis B 5

6 Among 47 patients who did experience HBeAg seroconversion, reactivation (loss of anti-hbe with reappearance of HBeAg) occurred in eight subjects within two years of follow-up This was significantly associated with HIV infection (5 of 14 HIV-seropositive patients compared with 3 of 33 HIV-seronegative patients) Di Martino V et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002; 123:1812. HBV Reactivation due to HIV 32 cases judged to be HBV reactivation 22/32 had sero-reversion to B surface Ag positivity 5 also had HBS antibody positivity Time of reactivation in relation to exposure to the anti-cd20 monoclonal antibody ranged from 63 days after the first dose to a year after the last dose. Screening with HBSAg and HBcore Ab recommended before using these drugs FDA Alert September 25, 2013 AntiCD20 Monoclonal Ab 6

7 Current CD4 was 50 cells/cmm, down from 340 one year prior HIV RNA 755,000 c/ml HBV DNA PCR 7,000 IU/mL Hepatitis C Ab negative Additional Labs CT scan nodular, cirrhotic-appearing liver with hypodense lesions, and large omental masses, with caking of the omentum and a large amount of ascites What about those hypodense lesions and omental masses? 7

8 Abdominal node biopsy by VIR diffuse, large, B-cell lymphoma Bone marrow and CSF negative for lymphoma Started HAART of tenofovir/emtricitabine (Truvada), raltegravir (Isentress) and etravirine (Intelence) Current CD4 48 cells/cmm and VL < 40 c/ml Hepatitis B DNA undetectable Received R-CHOP and is in full remission Rituxan held during first 2/6 cycles, until HBV fully suppressed with the tenofovir + emtricitabine (Truvada) Follow-up Latent HBV virus remains in the liver if previously infected, even though tests may show immunity Virus is never really gone Reactivation of HBV can occur from immune suppression Reactivation of HBV can occur after some monoclonal Ab therapies Take-Home Points 8

HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally

SEROLOGICAL TESTING FOR SUSPECTED VIRAL HEPATITIS Summary of the Clinical Practice Guideline January 2006 ALGORITHM FOR SUSPECTED ACUTE VIRAL HEPATITIS These recommendations are systematically developed

An overview of CLL care and treatment Dr Dean Smith Haematology Consultant City Hospital Nottingham What is CLL? CLL (Chronic Lymphocytic Leukaemia) is a type of cancer in which the bone marrow makes too

Review: How to work up your patient with Hepatitis C You screened your patient, and now the HCV antibody test is positive. What do you do next? The antibody test only means they have been exposed to HCV.

XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission

Transmission of HCV in the United States (CDC estimate) Past and Future US Incidence and Prevalence of HCV Infection Decline among IDUs Overall incidence Overall prevalence Infected 20+ years Armstrong

Screening for Bloodborne Pathogens in the Hemodialysis Unit A Sarabia MD Objectives To review the rationale for bloodborne pathogen screening To review relevant characteristics of bloodborne pathogen infections:

Track 2: Treatment Options [Narrator] Many people with non-hodgkin lymphoma have found an educational support group helpful. Support groups take many forms: some meet the needs of people with all kinds

Jaundice Michael Ornes Definitions Jaundice: hyperbilirubinemia leading to yellow discoloration of the skin Icterus: hyperbilirubinemia leading to yellow discoloration of the sclera Usually undetectable

Hepatitis C Fact Sheet February 2016 www.hepatitis.va.gov Laboratory Tests and Hepatitis If you have hepatitis C, your doctor will use laboratory tests to about learn more about your individual hepatitis

Hepatitis C Laboratory Tests and Hepatitis C If you have hepatitis C, your doctor will use laboratory tests to check your health. This handout will help you understand what the major tests are and what

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B

Hepatitis B in Pregnancy This guideline was updated in July 2015 by Dr Joana de Sousa, with input from members of the New Zealand Maternal Fetal Medicine Network and Neonatology. Background It is recognised

Anti-Infective Subcommittee of PTAC Meeting held 1 March 2012 (minutes for web publishing) Anti-Infective Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology

MARCH 2014 A Quick Guide to POST-EXPOSURE PROPHYLAXIS IN THE HEALTH CARE SETTING HIV PROVIDER REFERENCE SERIES A PUBLICATION OF THE MOUNTAIN PLAINS AIDS EDUCATION AND TRAINING CENTER MountainPlains AIDS

Is ISENTRESS right for you? Models ISENTRESS.com Provided as an educational resource by Merck INDICATION ISENTRESS is a prescription HIV-1 medicine used with other antiretroviral medicines to treat human

PERINATAL AND CHILDHOOD HEPATITIS.. WHAT ABOUT THE CHILDREN? John T. Stutts, MD, MPH University of Louisville School of Medicine Department of Pediatrics Division of Pediatric Gastroenterology, Hepatology

HOVON Staging and Response Criteria for Non-Hodgkin s Lymphomas Page 1 This document describes the minimally required staging and evaluation procedures and response criteria that will be applied in all

Summary The objective of the present work was to study the utility of serum procalcitonin for rapid and early diagnosis of bacterial infection in chronic liver diseases and to compare between serum PCT

Biological Therapies for Cancer Key Points Biological therapies use the body's immune system to fight cancer or to lessen the side effects that may be caused by some cancer treatments. Biological therapies

Scan for mobile link. Lymphoma Cancer Treatment What is Lymphoma? Lymphoma is a cancer that develops in the white blood cells (lymphocytes) of the lymphatic system, which is part of the body s immune system.

AASLD PRACTICE GUIDELINES Chronic Hepatitis B Anna S. F. Lok 1 and Brian J. McMahon 2 This guideline has been approved by the American Association for the Study of Liver Diseases and represents the position

LYMPHOMA IN DOGS Lymphoma is a relatively common cancer in dogs. It is a cancer of lymphocytes (a type of white blood cell) and lymphoid tissues. Lymphoid tissue is normally present in many places in the

Mountain West AIDS Education and Training Center Back to Basics: CMV Shireesha Dhanireddy, MD 21 July 2016 This presentation is intended for educational use only, and does not in any way constitute medical

POST-EXPOSURE PROPHYLAXIS (HIV, HEP B, HEP C) www.hiv-druginteractions.org No major changes to this protocol since last reviewed in 2014 Reference should also be made to the NHSGGC document on management

Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories

Produced 21.03.2011 Revision due 21.03.2011 Lymphomas after organ transplantation People who have undergone an organ transplant are more at risk of developing lymphoma known as post-transplant lymphoproliferative

HEPATITIS B VIRUS II. HEPATITIS B VIRUS Hepatitis B virus (HBV) is a major cause of acute and chronic hepatitis worldwide. In the United States, approximately 250,000 to 300,000 new HBV infections occur

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.

Update on Hepatitis C Sally Williams MD Hep C is Everywhere! Hepatitis C Magnitude of the Infection Probably 8 to 10 million people in the U.S. are infected with Hep C 30,000 new cases are diagnosed annually;